The National Pregnancy Registry for Antidepressants (NPRAD) is dedicated to evaluating the safety of antidepressant medications that may be taken during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy.


All pregnant people 45 and younger with a history of psychiatric illness are eligible to enroll in the registry. If you are interested in participating in the National Pregnancy Registry, please call the toll-free number above or fill out this Participant Interest Form to be contacted by a member of our research team. All information is kept strictly confidential.

More Information and Enrollment:

Antidepressants of interest to the National Pregnancy Registry include:

  • Celexa (citalopram)
  • Lexapro (escitalopram)
  • Luvox (fluvoxamine)
  • Paxil (paroxetine)
  • Prozac (fluoxetine)
  • Zoloft (sertraline)
  • Cymbalta (duloxetine)
  • Effexor (venlafaxine)
  • Fetzima (levomilnacipran)
  • Pristiq (desvenlafaxine)
  • Serzone (nefazodone)
  • Anafranil (clomipramine)
  • Asendin (amoxapine)
  • Elavil (amitriptyline)
  • Ludiomil (maprotiline)
  • Norpramin (desipramine)
  • Pamelor (nortriptyline)
  • Sinequan (doxepin)
  • Surmontil (trimipramine)
  • Tofranil (imipramine)
  • Vivactil (protriptyline)
  • Marplan (isocarboxazid)
  • Nardil (phenelzine)
  • Parnate (tranylcypromine)
  • Brintellix (vortioxetine)
  • Desyrel (trazodone)
  • Remeron (mirtazapine)
  • Wellbutrin (buproprion)
  • Spravato (esketamine)
  • Zulresso (brexanolone)

Required Sponsorship Disclosures:

Current Sponsors: Alkermes, Inc. (2016-Present); Dr. Reddy’s Laboratories, Inc. (2023-Present); Eisai Inc. (2022 – Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).

Past Sponsors: Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present); Aurobindo Pharma (2020-2022, declined to sponsor: 2022-Present); AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); AuroMedics Pharma LLC (2021-2022, declined to sponsor: 2022-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-2023, declined to sponsor: 2024-Present) ; Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present); Sage Therapeutics (2019-2023, declined to sponsor 2024-present); Sunovion Pharmaceuticals, Inc. (2011-2023, declined to sponsor: 2024-Present).

Declined to sponsor: AbbVie Inc.; Ajanta Pharma USA Inc.; Apotex Inc.; Arcolab Private Limited; Eli Lilly and Company; Intra-Cellular Therapies, Inc.; Novartis Pharmaceuticals; Qilu Pharmaceutical Co., Ltd.; Vanda Pharmaceuticals Inc.

Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.